Devised and led the Social Media campaign for the U.S. FDA Approval of SPRAVATO® (esketamine) Nasal Spray to treat Depressive symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior (Janssen)
SPRAVATO® is the first and only approved antidepressant medication shown to begin improving depressive symptoms with the first dose (24 hours).
Tactics Included:
LinkedIn: Physician/Mental Health Provider-focused Video Series and Whitepapers
Twitter: Influencer Campaign, Consumer-targeted educational campaign
Facebook: Private community creation and engagement
